• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    OptimizeRx Sets First Quarter 2025 Conference Call for May 12, 2025, at 4:30 p.m. ET

    4/23/25 7:30:00 AM ET
    $OPRX
    Business Services
    Consumer Discretionary
    Get the next $OPRX alert in real time by email

    WALTHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Monday, May 12, 2025, at 4:30 p.m. Eastern Time to discuss its results for the first quarter period ended March 31, 2025. The financial results will be issued in a press release prior to the call.

    OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below:

    Date:Monday, May 12, 2025
    Time:4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)
    Toll Free:1-844-825-9789
    International:1-412-317-5180
    Conference ID:10198829
    Call me™ Link:https://callme.viavid.com/?$Y2FsbG1lPXRydWUmcGFzc2NvZGU9JmluZm89Y29tcGFueSZyPXRydWUmYj0xNg==
    Call me™ Passcode:8199416
    Webcast:https://viavid.webcasts.com/starthere.jsp?ei=1715418&tp_key=2f5165024a



    Please call the conference telephone number or log on to the web access link five minutes prior to the start time.

    A replay of the call will remain available for 12 months via the Investors section of the OptimizeRx website at http://www.optimizerx.com/investors.  

    About OptimizeRx

    OptimizeRx provides trailblazing technology that fosters care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the healthcare journey. With the ability to synchronize messaging across 2 million healthcare providers and over 240 million adults across a multitude of digital channels including a proprietary point-of-care network, OptimizeRx is changing the way life sciences engage with customers.

    For more information, follow the Company on X, LinkedIn or visit www.optimizerx.com. 

    OptimizeRx Contact 

    Andy D'Silva, SVP Corporate Finance

    [email protected]

    Investor Relations Contact

    Steven Halper

    LifeSci Advisors, LLC

    [email protected]



    Primary Logo

    Get the next $OPRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OPRX

    DatePrice TargetRatingAnalyst
    1/8/2025$7.00 → $6.00Outperform → Sector Perform
    RBC Capital Mkts
    12/20/2024$5.50Equal-Weight
    Stephens
    7/25/2024$18.50Buy
    B. Riley Securities
    4/4/2024$15.00Mkt Outperform
    JMP Securities
    1/3/2024$15.00Equal Weight
    Barclays
    2/2/2023$30.00Buy
    B. Riley Securities
    11/1/2022$19.00Buy
    Stifel
    7/15/2022$38.00Outperform
    SVB Leerink
    More analyst ratings

    $OPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • OptimizeRx downgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts downgraded OptimizeRx from Outperform to Sector Perform and set a new price target of $6.00 from $7.00 previously

      1/8/25 8:17:01 AM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • Stephens initiated coverage on OptimizeRx with a new price target

      Stephens initiated coverage of OptimizeRx with a rating of Equal-Weight and set a new price target of $5.50

      12/20/24 7:46:38 AM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • B. Riley Securities resumed coverage on OptimizeRx with a new price target

      B. Riley Securities resumed coverage of OptimizeRx with a rating of Buy and set a new price target of $18.50

      7/25/24 8:24:56 AM ET
      $OPRX
      Business Services
      Consumer Discretionary

    $OPRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Klema Cathy was granted 9,868 shares, increasing direct ownership by 84% to 21,620 units (SEC Form 4)

      4 - OptimizeRx Corp (0001448431) (Issuer)

      6/12/25 4:36:16 PM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • Director Lang James Paul was granted 9,868 shares, increasing direct ownership by 3% to 399,320 units (SEC Form 4)

      4 - OptimizeRx Corp (0001448431) (Issuer)

      6/12/25 4:35:31 PM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • Director Spangler Patrick D was granted 9,868 shares, increasing direct ownership by 22% to 55,335 units (SEC Form 4)

      4 - OptimizeRx Corp (0001448431) (Issuer)

      6/12/25 4:34:57 PM ET
      $OPRX
      Business Services
      Consumer Discretionary

    $OPRX
    SEC Filings

    See more
    • OptimizeRx Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - OptimizeRx Corp (0001448431) (Filer)

      6/24/25 7:45:08 AM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • OptimizeRx Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - OptimizeRx Corp (0001448431) (Filer)

      6/16/25 4:29:49 PM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • SEC Form 10-Q filed by OptimizeRx Corporation

      10-Q - OptimizeRx Corp (0001448431) (Filer)

      5/13/25 4:04:23 PM ET
      $OPRX
      Business Services
      Consumer Discretionary

    $OPRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Lang James Paul bought $2,443,761 worth of shares (321,408 units at $7.60), increasing direct ownership by 472% to 389,452 units (SEC Form 4)

      4 - OptimizeRx Corp (0001448431) (Issuer)

      3/19/25 7:40:24 PM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • CEO Febbo William J bought $100,220 worth of shares (20,000 units at $5.01), increasing direct ownership by 3% to 601,253 units (SEC Form 4)

      4 - OptimizeRx Corp (0001448431) (Issuer)

      12/16/24 2:28:39 PM ET
      $OPRX
      Business Services
      Consumer Discretionary

    $OPRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • OptimizeRx Corporation Appoints CEO Steve Silvestro to Board of Directors

      WALTHAM, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced the appointment of Steve Silvestro, currently serving as the Company's Chief Executive Officer, to its Board of Directors, effective as of June 20, 2025. Mr. Silvestro joined the Company in 2019 and has been the Company's CEO since March 2025, after serving as the interim CEO from January 2025. The appointment of Mr. Silvestro, with his knowledge of the Company and expertise in the industry, will enhance overall leadership and gre

      6/24/25 7:30:00 AM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • Simulmedia and OptimizeRx Announce Partnership from the Cannes Lions

      Strategic Collaboration Brings Precision Micro-Neighborhood® Targeting Healthcare Consumer Audiences to Linear and Connected TV Simulmedia, a national leader in data-driven TV and streaming advertising, today announced a strategic partnership with OptimizeRx Corp. (NASDAQ:OPRX), a leading provider of healthcare technology solutions, to enable the self-serve availability of Micro-Neighborhood® Targeting (MNT) audiences across linear, digital, and connected TV (CTV) channels. This collaboration allows healthcare brands—especially small and mid-size pharmaceutical companies and in-house planning teams—to activate clinically precise audiences across guaranteed premium TV and streaming inven

      6/18/25 3:00:00 AM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • OptimizeRx to Participate in Upcoming Investor Conferences

      WALTHAM, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences: B. Riley Securities 25th Annual Investor Conference, Marina del Rey, May 21 – 22, 2025Stifel 2025 Boston Cross Sector 1x1 Conference, Boston, June 3 – 4, 202545th Annual William Blair Growth Stock Conference, Chicago, June 3 – 5, 2025The Citizens Medical Devices and Healthcare Services Forum, Boston, June 17, 2025 B. Riley Securities 25th Annual Invest

      5/16/25 7:30:00 AM ET
      $OPRX
      Business Services
      Consumer Discretionary